Publikationen

Aktuelle Veröffentlichungen (Auswahl)

Balint N, Woopen H, Richter R, Pirmorady-Sehouli A, Pietzner K, Sehouli J. Sexuality as a Prognostic Factor—Results of an Individual Patient Data NOGGO (North-Eastern German Society of Gynecological Oncology)-Meta-Analysis of 644 Recurrent Ovarian Cancer Patients Prior to Chemotherapy.Cancers (Basel). 2024;16(4):811. doi: 10.3390/cancers16040811.

Beck MH, Balci-Hakimeh D, Scheuerecker F, Wallach C, Güngor HL, Lee M, Abdel-Kawi AF, Glajzer J, Vasiljeva J, Kubiak K, Blohmer JU, Sehouli J, Pietzner K. Real-World Evidence: How Long Do Our Patients Fast?-Results from a Prospective JAGO-NOGGO-Multicenter Analysis on Perioperative Fasting in 924 Patients with Malignant and Benign Gynecological Diseases. Cancers (Basel). 2023;15(4):1311. doi: 10.3390/cancers15041311.

Biersack MG, Volmer LL, Geißler C, Fromme J, Fröhlich S, Pietzner K, Sehouli J, Beck MH. Informed consent in gynecological oncology: a JAGO/NOGGO survey on real-world practices in daily clinical routine. Arch Gynecol Obstet. 2025 Feb;311(2):451-457. doi: 10.1007/s00404-024-07776-9.

Chinczewski L, Harter P, Heukamp L, Mayr D, Grimm C, Heinzelmann-Schwarz V, Wimberger P, Mahner S, Braicu IE, Schmitt W, Denkert C, Sehouli J. Intergroup-statement: statement of the german ovarian cancer commission, the North-Eastern German Society of gynecological Oncology (NOGGO), AGO Austria and AGO Swiss regarding the use of homologous repair deficiency (HRD) assays in advanced ovarian cancer.Arch Gynecol Obstet. 2025 May;311(5):1445-1450. doi: 10.1007/s00404-025-07991-y.

Dimitrova D, Boer J, Karaman M, Bookman M, Brand A, O'Donnell J, Oza A, Pothuri B, Bennett K, Sehouli J. Perspectives on inclusion, diversity, equity, and access in clinical trials: findings from a six-continent survey. Int J Gynecol Cancer. 2025;101625. doi: 10.1016/j.ijgc.2024.101625.

Herzog EM, Pirmorady Sehouli A, Boer J, Pietzner K, Petru E, Heinzelmann V, Roser E, Dimitrova D, Oskay-Özcelik G, Camara O, Sehouli J. How to break bad news and how to learn this skill: results from an international North-Eastern German Society for Gynecological Oncology (NOGGO) survey among physicians and medical students with 1089 participants. Int J Gynecol Cancer. 2023;33(12):1934-1942. doi: 10.1136/ijgc-2023-004693.

Inci MG, Ilter E, Roser E, Dimitrova D, Kofiah R, Stoklossa C, Karaman M, Goerling U, Plett H, Aktas B, Mangler M, Lanowska M, Oskay-Oeczelik G, Barinoff J, Wimberger P, Pirmorady-Sehouli A, Schmalfeldt B, Mayr D, Letsch A, Maass N, Harter P, Mahner S, Hanf V, Hasenburg A, Sehouli J. Experiences and expectations of advance directives in gynecological cancer patients (The NOGGO-Expression X Study).Int J Gynecol Cancer. 2025;102008. doi:10.1016/j.ijgc.2025.102008.

Lindemann K, Berton D, Sehouli J, Christensen RD, Altintas S, Knudsen AØ, Heudel PE, Ataseven B, Vergote I, Lindahl G, Lebreton C, Schochter F, Auranen A, Follana P, Madsen K, Selle F, Petersson KS, Joly F, Braicu EI, Mirza MR. NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer. Gynecol Oncol. 2025 Jun 30;199:79-87. doi: 10.1016/j.ygyno.2025.06.008.

Mirza MR, Bjørge L, Marmé F, Christensen RD, Gil-Martin M, Auranen A, Ataseven B, Rubio MJ, Salutari V, Luczak AA, Runnebaum IB, Redondo A, Lindemann K, Trillsch F, Ginesta MPB, Roed H, Kurtz JE, Petersson KS, Nyvang GB, Sehouli J. Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial. Gynecol Oncol. 2025 Jan;192:128-136. doi: 10.1016/j.ygyno.2024.12.003.

Pfarr N, von Schwarzenberg K, Zocholl D, Merkelbach-Bruse S, Siemanowski J, Mayr EM, Herold S, Kleo K, Heukamp LC, Willing EM, Menzel M, Lehmann U, Bartels S, Chakraborty S, Baretton G, Demes MC, Döring C, Kazdal D, Budczies J, Rad R, Wild P, Christinat Y, McKee T, Schirmacher P, Horst D, Büttner R, Stenzinger A, Sehouli J, Vollbrecht C, Hummel M, Braicu EI, Weichert W. German HRD assay Harmonization Consortium. High Concordance of Different Assays in the Determination of Homologous Recombination Deficiency-Associated Genomic Instability in Ovarian Cancer. JCO Precis Oncol. 2024;e2300348. doi: 10.1200/PO.23.00348.

Riedel M, Herrmann H, Bartl T, Rossner AM, Tatzber A, Flethe C, Zocholl D, Schmalfeldt B, Sehouli J, Pietzner K. The implementation and side effect management of immune checkpoint inhibitors in gynecologic oncology: a JAGO/NOGGO survey. BMC Cancer. 2025 Jan 29;25(1):170. doi: 10.1186/s12885-025-13432-5.

Sehouli J, Boer J, Brand AH, Oza AM, O'Donnell J, Bennett K, Glaspool R, Lee CK, Ethier JL, Harter P, Seebacher-Shariat V, Chang TC, Cohen PA, van Gorp T, Chavez-Blanco A, Welch S, Hranovska H, O'Toole S, Lok CAR, Madariaga A, Rauh-Hain JA, Perez Fidalgo A, Tan D, Michels J, Pothuri B, Fujiwara N, Rosengarten O, Nishio H, Kim SI, Mukopadhyay A, Piovano E, Cecere SC, Kohn EC, Mukherjee U, Nasser S, Lindemann K, Croke J, Chen X, Geissler F, Bookman MA. How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting. Int J Gynecol Cancer. 2024 Nov 4;34(11):1677-1684. doi: 10.1136/ijgc-2024-005982.

Westin SN, Moore K, Chon HS, Lee JY, Thomes Pepin J, Sundborg M, Shai A, de la Garza J, Nishio S, Gold MA, Wang K, McIntyre K, Tillmanns TD, Blank SV, Liu JH, McCollum M, Contreras Mejia F, Nishikawa T, Pennington K, Novak Z, De Melo AC, Sehouli J, Klasa-Mazurkiewicz D, Papadimitriou C, Gil-Martin M, Brasiuniene B, Donnelly C, Del Rosario PM, Liu X, Van Nieuwenhuysen E; DUO-E Investigators. Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial. J Clin Oncol. 2024;42(3):283-299. doi: 10.1200/JCO.23.02132.

Willing EM, Vollbrecht C, Vössing C, Weist P, Schallenberg S, Herbst JM, Schatz S, Jóri B, Bataillon G, Harter P, Salutari V, Martin AG, Vergote I, Colombo N, Roeper J, Berg T, Berger R, Kah B, Noettrup TJ, Falk M, Arndt K, Polten A, Ray-Coquard I, Selzam F, Pirngruber J, Schmidt S, Hummel M, Tiemann M, Horst D, Sehouli J, Pujade-Lauraine E, Tiemann K, Braicu EI, Heukamp LC. Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation. Cancers (Basel). 2023;15(13):3445. doi: 10.3390/cancers15133445.

Woopen H, Keller M, Zocholl D, Mittelstadt S, Barretina-Ginesta MP, Heinzelmann-Schwarz V, Lafleur J, Kocián R, Baum J, Krabisch P, Achimas-Cadariu P, Vardar MA, Vergote I, Nasser S, Link T, Gil-Martin M, Zwimpfer TA, Leitner K, Jedryka M, Boxler T, Braicu EI, Sehouli J. Side Effects from Cancer Therapies and Perspective of 1044 Long-Term Ovarian Cancer Survivors—Results of Expression VI–Carolin Meets HANNA–Holistic Analysis of Long-Term Survival with Ovarian Cancer: The International NOGGO, ENGOT, and GCIG Survey. Cancers (Basel). 2023;15(22):5428. doi: 10.3390/cancers15225428.

letzte Aktualisierung: 29.07.2025